(NASDAQ: ALPN) Alpine Immune Sciences's forecast annual revenue growth rate of -10.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Alpine Immune Sciences's revenue in 2024 is $58,876,000.On average, 3 Wall Street analysts forecast ALPN's revenue for 2024 to be $1,463,841,855, with the lowest ALPN revenue forecast at $786,553,632, and the highest ALPN revenue forecast at $2,621,845,440. On average, 2 Wall Street analysts forecast ALPN's revenue for 2025 to be $2,621,845,440, with the lowest ALPN revenue forecast at $2,621,845,440, and the highest ALPN revenue forecast at $2,621,845,440.
In 2026, ALPN is forecast to generate $2,294,770,221 in revenue, with the lowest revenue forecast at $2,294,770,221 and the highest revenue forecast at $2,294,770,221.